The acquired portfolio includes Ultracain®, a local and infiltrative anesthetic, Rodogyl® and Birodogyl®, treatments of acute chronic or recurrent stomatological infections, and Dontisolon®, an anti-inflammatory, decongestant and analgesic oral paste.
“These brands are great additions to Septodont’s existing dental portfolio and will allow us to strengthen the value proposition we bring to our customers through a broader range of products and solutions”, says Olivier Schiller, CEO of the Septodont’s Group.
“They not only cover complementary dentistry indications such as aesthetics, anti-infective and anti-inflammatory, but will also significantly grow Septodont’s business in Europe, particularly in Germany, as well as in several other key markets in Asia and North Africa. This is consistent with our strategy, ambition and commitment to continue our growth trajectory by strengthening our activities and by accelerating our ability to grow and compete in the dental space.”
“With this acquisition, Septodont will also contribute to the local economic development by investing in a state-of-the art €35 million manufacturing facility and creating 60 jobs at its Saint-Maur-des-Fossés site”, said Olivier Schiller.
The transaction is subject to closing conditions and, if satisfied, is likely to complete by the end of the year.
The agreement covers the registrations, trademarks and related commercial rights of the products in scope. It is structured as an asset purchase. No employees, equipment or real estate is included.